|
2025-03-25 |
2025-03-24 |
PS
Planned sale
|
Sacco Tracey
Chief Commercial Officer
Officer
|
5,000
-6.5%
32.89
USD 164,459
|
5,000
-6.5%
|
32.89
|
USD 164,459
|
|
|
2025-03-25 |
2025-03-24 |
PS
Planned sale
|
Sacco Tracey
Chief Commercial Officer
Officer
|
1,500
-1.9%
33.70
USD 50,556
|
1,500
-1.9%
|
33.70
|
USD 50,556
|
|
|
2025-03-25 |
2025-03-24 |
PS
Planned sale
|
Moore Erin
Interim PFO and PAO
Officer
|
13,564
-14.1%
33.12
USD 449,237
|
13,564
-14.1%
|
33.12
|
USD 449,237
|
|
|
2025-03-19 |
2025-03-17 |
PS
Planned sale
|
Peng Katie
Non-Executive Director
|
1,006
-3.2%
34.42
USD 34,627
|
1,006
-3.2%
|
34.42
|
USD 34,627
|
|
|
2025-03-12 |
2025-03-10 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
29,395
-20.9%
34.87
USD 1,025,004
|
29,395
-20.9%
|
34.87
|
USD 1,025,004
|
|
|
2025-03-12 |
2025-03-10 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
112,897
-44.5%
35.82
USD 4,043,971
|
112,897
-44.5%
|
35.82
|
USD 4,043,971
|
|
|
2025-02-20 |
2025-02-19 |
PS
Planned sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
20,202
-15.4%
37.74
USD 762,498
|
20,202
-15.4%
|
37.74
|
USD 762,498
|
|
|
2025-02-20 |
2025-02-19 |
PS
Planned sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
8,341
-6.0%
37.56
USD 313,289
|
8,341
-6.0%
|
37.56
|
USD 313,289
|
|
|
2025-02-20 |
2025-02-19 |
PS
Planned sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
39,967
-22.3%
37.20
USD 1,486,692
|
39,967
-22.3%
|
37.20
|
USD 1,486,692
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
4,135
-3.1%
36.83
USD 152,288
|
4,135
-3.1%
|
36.83
|
USD 152,288
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
5,296
-3.6%
36.83
USD 195,046
|
5,296
-3.6%
|
36.83
|
USD 195,046
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Myles Edward H
COO & CFO
Officer
|
7,809
-5.3%
36.83
USD 287,598
|
7,809
-5.3%
|
36.83
|
USD 287,598
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Ho Junlin
GENERAL COUNSEL
Officer
|
5,742
-2.9%
36.83
USD 211,472
|
5,742
-2.9%
|
36.83
|
USD 211,472
|
|
|
2025-02-20 |
2025-02-18 |
S
Sale
|
Backstrom Jay T.
CHIEF EXECUTIVE OFFICER
Executive Director
|
18,372
-5.6%
36.83
USD 676,622
|
18,372
-5.6%
|
36.83
|
USD 676,622
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Ho Junlin
GENERAL COUNSEL
Officer
|
9,039
-4.4%
44.20
USD 399,498
|
9,039
-4.4%
|
44.20
|
USD 399,498
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
7,347
-5.1%
44.20
USD 324,717
|
7,347
-5.1%
|
44.20
|
USD 324,717
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Myles Edward H
COO & CFO
Officer
|
12,539
-7.8%
44.20
USD 554,189
|
12,539
-7.8%
|
44.20
|
USD 554,189
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Sacco Tracey
Chief Commercial Officer
Officer
|
3,890
-7.9%
44.20
USD 171,927
|
3,890
-7.9%
|
44.20
|
USD 171,927
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
6,434
-4.2%
44.20
USD 284,365
|
6,434
-4.2%
|
44.20
|
USD 284,365
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
5,655
-7.8%
44.20
USD 249,935
|
5,655
-7.8%
|
44.20
|
USD 249,935
|
|
|
2025-01-21 |
2025-01-16 |
S
Sale
|
Backstrom Jay T.
CHIEF EXECUTIVE OFFICER
Executive Director
|
22,308
-6.3%
44.20
USD 985,951
|
22,308
-6.3%
|
44.20
|
USD 985,951
|
|
|
2024-12-12 |
2024-12-10 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
1,600,000
-14.7%
41.65
USD 66,640,000
|
1,600,000
-14.7%
|
41.65
|
USD 66,640,000
|
|
|
2024-11-27 |
2024-11-25 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
149
-0.0%
40.98
USD 6,106
|
149
-0.0%
|
40.98
|
USD 6,106
|
|
|
2024-11-27 |
2024-11-25 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
30,683
-0.3%
40.14
USD 1,231,585
|
30,683
-0.3%
|
40.14
|
USD 1,231,585
|
|
|
2024-11-27 |
2024-11-25 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
126,442
-1.1%
39.51
USD 4,995,774
|
126,442
-1.1%
|
39.51
|
USD 4,995,774
|
|
|
2024-11-27 |
2024-11-25 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
43,887
-0.4%
38.43
USD 1,686,670
|
43,887
-0.4%
|
38.43
|
USD 1,686,670
|
|
|
2024-11-27 |
2024-11-25 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
208,272
-1.8%
37.63
USD 7,837,504
|
208,272
-1.8%
|
37.63
|
USD 7,837,504
|
|
|
2024-11-26 |
2024-11-25 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
200
-0.3%
40.72
USD 8,144
|
200
-0.3%
|
40.72
|
USD 8,144
|
|
|
2024-11-26 |
2024-11-25 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
3,075
-4.0%
39.93
USD 122,780
|
3,075
-4.0%
|
39.93
|
USD 122,780
|
|
|
2024-11-26 |
2024-11-25 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
2,100
-2.7%
39.25
USD 82,434
|
2,100
-2.7%
|
39.25
|
USD 82,434
|
|
|
2024-11-26 |
2024-11-25 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
1,000
-1.3%
38.04
USD 38,041
|
1,000
-1.3%
|
38.04
|
USD 38,041
|
|
|
2024-11-26 |
2024-11-22 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
2,145
-2.9%
30.01
USD 64,372
|
2,145
-2.9%
|
30.01
|
USD 64,372
|
|
|
2024-11-13 |
2024-11-11 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
2,105
-2.8%
30.00
USD 63,158
|
2,105
-2.8%
|
30.00
|
USD 63,158
|
|
|
2024-10-10 |
2024-10-08 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
37,187
-18.8%
34.90
USD 1,297,659
|
37,187
-18.8%
|
34.90
|
USD 1,297,659
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
39,375
-35.1%
30.06
USD 1,183,652
|
39,375
-35.1%
|
30.06
|
USD 1,183,652
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
2,552
-2.2%
26.22
USD 66,923
|
2,552
-2.2%
|
26.22
|
USD 66,923
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Marantz Jing L.
CHIEF MEDICAL OFFICER
Officer
|
67,448
-37.0%
25.59
USD 1,725,893
|
67,448
-37.0%
|
25.59
|
USD 1,725,893
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Sacco Tracey
CHIEF COMMERCIAL OFFICER
Officer
|
1,964
-3.8%
26.23
USD 51,516
|
1,964
-3.8%
|
26.23
|
USD 51,516
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Sacco Tracey
CHIEF COMMERCIAL OFFICER
Officer
|
28,036
-35.4%
25.58
USD 717,161
|
28,036
-35.4%
|
25.58
|
USD 717,161
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
31,250
-16.2%
29.05
USD 907,813
|
31,250
-16.2%
|
29.05
|
USD 907,813
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
25,812
-11.8%
27.27
USD 703,893
|
25,812
-11.8%
|
27.27
|
USD 703,893
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
37,206
-14.6%
26.83
USD 998,237
|
37,206
-14.6%
|
26.83
|
USD 998,237
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
111,972
-30.5%
25.61
USD 2,867,603
|
111,972
-30.5%
|
25.61
|
USD 2,867,603
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
AKKARAJU SRINIVAS
Non-Executive Director
|
155,713
-2.7%
32.50
USD 5,060,673
|
155,713
-2.7%
|
32.50
|
USD 5,060,673
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
AKKARAJU SRINIVAS
Non-Executive Director
|
510,000
-8.1%
30.00
USD 15,300,000
|
510,000
-8.1%
|
30.00
|
USD 15,300,000
|
|
|
2024-10-07 |
2024-10-07 |
PS
Planned sale
|
AKKARAJU SRINIVAS
Non-Executive Director
|
510,000
-7.5%
27.50
USD 14,025,000
|
510,000
-7.5%
|
27.50
|
USD 14,025,000
|
|
|
2024-09-19 |
2024-09-16 |
S
Sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
1,936
-1.3%
8.58
USD 16,611
|
1,936
-1.3%
|
8.58
|
USD 16,611
|
|
|
2024-08-19 |
2024-08-16 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
1,451
-0.9%
9.33
USD 13,538
|
1,451
-0.9%
|
9.33
|
USD 13,538
|
|
|
2024-06-18 |
2024-06-17 |
S
Sale
|
Myles Edward H
COO & CFO
Officer
|
9,458
-4.5%
8.98
USD 84,978
|
9,458
-4.5%
|
8.98
|
USD 84,978
|
|
|
2024-06-18 |
2024-06-17 |
S
Sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
2,315
-1.6%
8.99
USD 20,800
|
2,315
-1.6%
|
8.99
|
USD 20,800
|
|
|
2024-06-18 |
2024-06-17 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
4,305
-2.7%
8.98
USD 38,680
|
4,305
-2.7%
|
8.98
|
USD 38,680
|
|
|
2024-06-18 |
2024-06-17 |
S
Sale
|
Ho Junlin
GENERAL COUNSEL
Officer
|
4,695
-2.2%
8.98
USD 42,183
|
4,695
-2.2%
|
8.98
|
USD 42,183
|
|
|
2024-02-21 |
2024-02-16 |
S
Sale
|
Myles Edward H
COO & CFO
Officer
|
4,744
-2.2%
15.74
USD 74,686
|
4,744
-2.2%
|
15.74
|
USD 74,686
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
3,751
-2.3%
15.74
USD 59,053
|
3,751
-2.3%
|
15.74
|
USD 59,053
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Ho Junlin
GENERAL COUNSEL
Officer
|
3,489
-1.6%
15.74
USD 54,928
|
3,489
-1.6%
|
15.74
|
USD 54,928
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Qatanani Mo
CHIEF SCIENTIFIC OFFICER
Officer
|
2,512
-1.7%
15.74
USD 39,547
|
2,512
-1.7%
|
15.74
|
USD 39,547
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Backstrom Jay T.
CHIEF EXECUTIVE OFFICER
Executive Director
|
11,614
-3.2%
15.74
USD 182,842
|
11,614
-3.2%
|
15.74
|
USD 182,842
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Ho Junlin
GENERAL COUNSEL
Officer
|
4,186
-2.6%
15.93
USD 66,677
|
4,186
-2.6%
|
15.93
|
USD 66,677
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Qatanani Mo
SVP AND HEAD OF RESEARCH
Officer
|
2,002
-2.5%
15.93
USD 31,889
|
2,002
-2.5%
|
15.93
|
USD 31,889
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
2,849
-2.4%
15.93
USD 45,381
|
2,849
-2.4%
|
15.93
|
USD 45,381
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Myles Edward H
COO & CFO
Officer
|
6,634
-3.9%
15.93
USD 105,670
|
6,634
-3.9%
|
15.93
|
USD 105,670
|
|
|
2023-12-29 |
2023-12-29 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
300
-0.2%
19.51
USD 5,853
|
300
-0.2%
|
19.51
|
USD 5,853
|
|
|
2023-12-29 |
2023-12-29 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
12,159
-6.7%
18.82
USD 228,780
|
12,159
-6.7%
|
18.82
|
USD 228,780
|
|
|
2023-12-15 |
2023-12-14 |
S
Sale
|
Qatanani Mo
SVP AND HEAD OF RESEARCH
Officer
|
24,662
-23.4%
18.18
USD 448,444
|
24,662
-23.4%
|
18.18
|
USD 448,444
|
|
|
2023-12-08 |
2023-12-07 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
24,914
-12.9%
17.53
USD 436,820
|
24,914
-12.9%
|
17.53
|
USD 436,820
|
|
|
2023-11-03 |
2023-11-02 |
PS
Planned sale
|
Myles Edward H
COO & CFO
Officer
|
35,007
-17.2%
12.51
USD 438,039
|
35,007
-17.2%
|
12.51
|
USD 438,039
|
|
|
2023-10-18 |
2023-10-16 |
B
Purchase
|
Samsara BioCapital GP, LLC
Large shareholder
|
2,189,781
+47.6%
6.85
USD 15,000,000
|
2,189,781
+47.6%
|
6.85
|
USD 15,000,000
|
|
|
2023-10-18 |
2023-10-16 |
B
Purchase
|
AKKARAJU SRINIVAS
Non-Executive Director
Large shareholder
|
2,189,781
+47.6%
6.85
USD 15,000,000
|
2,189,781
+47.6%
|
6.85
|
USD 15,000,000
|
|
|
2023-10-16 |
2023-10-12 |
B
Purchase
|
Invus Public Equities, L.P.
Large shareholder
|
10,150
+0.1%
8.55
USD 86,736
|
10,150
+0.1%
|
8.55
|
USD 86,736
|
|
|
2023-10-16 |
2023-10-12 |
B
Purchase
|
Invus Public Equities, L.P.
Large shareholder
|
2,189,781
+24.2%
6.85
USD 15,000,000
|
2,189,781
+24.2%
|
6.85
|
USD 15,000,000
|
|
|
2023-09-20 |
2023-09-18 |
S
Sale
|
Qatanani Mo
SVP AND HEAD OF RESEARCH
Officer
|
1,945
-2.0%
6.34
USD 12,331
|
1,945
-2.0%
|
6.34
|
USD 12,331
|
|
|
2023-08-18 |
2023-08-16 |
S
Sale
|
Parlavecchio Caryn
CHRO
Officer
|
1,353
-1.1%
6.83
USD 9,241
|
1,353
-1.1%
|
6.83
|
USD 9,241
|
|
|
2023-05-02 |
2023-04-28 |
B
Purchase
|
Invus Public Equities, L.P.
Large shareholder
|
31,557
+0.3%
6.43
USD 202,845
|
31,557
+0.3%
|
6.43
|
USD 202,845
|
|
|
2023-01-11 |
2023-01-09 |
S
Sale
|
Invus Public Equities, L.P.
Large shareholder
|
1,094
-0.0%
9.48
USD 10,373
|
1,094
-0.0%
|
9.48
|
USD 10,373
|
|
|
2023-01-09 |
2023-01-05 |
B
Purchase
|
Invus Public Equities, L.P.
Large shareholder
|
48,774
+0.5%
9.33
USD 455,091
|
48,774
+0.5%
|
9.33
|
USD 455,091
|
|
